Journal of Ophthalmology / 2017 / Article / Tab 2 / Review Article
Safety and Efficacy of Microinvasive Glaucoma Surgery Table 2 Efficacy of MIGS devices.
Author Year Operation Number of eyes Follow-up (months) Preop IOP (mmHg) Postop IOP (mmHg) IOP reduction (mmHg, %) Preop meds Postop meds Medication reduction (n , %) Schlemm’s canal devices Trabectome Wecker et al. [39 ] 2016 Trabectome ± CS 60 12 24.5 ± 3.5 15.7 ± 3.4 8.8 (35.9) 2.1 ± 1.3 1.8 ± 1.2 0.3 (14.3) Lee et al. [38 ] 2016 Trabectome 17 6 24.4 ± 4.4 16.9 ± 5.1 7.5 (30.7) 3.9 ± 0.8 2.8 ± 1.6 1.1 (28.2) Jordan et al. [40 ] 2013 Trabectome ± CS 261 6 24.2 ± 5.5 18.2 ± 6.1 6 (24.8) 2.1 ± 1.3 1.2 ± 1.1 0.9 (42.9) Bussel et al. [37 ] 2015 Trabectome 58 12 23.7 ± 5.5 16.2 ± 3.9 7.5 (31.6) 2.8 ± 1.2 2.0 ± 1.3 0.8 (28.6) Trabectome ± CS 15 12 20 ± 5.9 15.6 ± 5.1 4.4 (22.0) 2.5 ± 1.5 1.6 ± 1.4 0.9 (36.0) Maeda et al. [64 ] 2013 Trabectome 80 6 26.6 ± 8.1 17.4 ± 3.4 9.2 (34.6) 4.0 ± 1.4 2.3 ± 1.2 1.7 (42.5) Ting et al. [36 ] 2012 Trabectome 450 12 25.5 ± 7.9 16.8 ± 3.9 8.7 (34.1) 2.7 ± 1.3 2.2 ± 1.3 0.5 (20.9) Trabectome 67 12 29 ± 7.5 16.1 ± 4.0 12.9 (44.5) 3.1 ± 1.2 2.2 ± 1.4 0.8 (28.5) Trabectome ± CS 263 12 19.9 ± 5.4 15.6 ± 3.2 4.3 (21.6) 2.4 ± 1.1 1.7 ± 1.3 0.8 (31.3) Trabectome ± CS 45 12 21.7 ± 8.4 14.2 ± 3.1 7.5 (34.6) 2.5 ± 1.0 1.6 ± 1.3 1.0 (37.9) Francis et al. [42 ] 2008 Trabectome ± CS 304 12 20 ± 6.3 15.5 ± 2.9 4.5 (22.5) 2.7 ± 1.1 1.4 ± 1.3 1.2 (45.7) Minckler et al. [35 ] 2005 Trabectome 37 12 28.2 ± 4.4† 16.3 ± 2.0 11.9 (42.2) 1.2 ± 0.6 0.4 ± 0.6 0.8 (66.7) ELT Babighian et al. [49 ] 2010 ELT 15 24 25.0 ± 1.9 17.6 ± 2.2 7.4 (29.6) 2.2 ± 0.6 0.7 ± 0.8 1.5 (66.8) Wilmsmeyer et al. [48 ] 2006 ELT 75 12 23.3 ± 0.6 18.8 ± 0.8 4.5 (19.3) 1.9 ± 0.1 1.8 ± 0.2 0.1 (5.3) ELT + CS 60 12 22.4 ± 0.8 16.4 ± 0.4 6.0 (26.8) 1.1 ± 0.2 1.2 ± 0.2 −0.1 (−9.1) iStent Vold et al. [15 ] 2016 2 iStents 54 36 25.5 ± 2.5 14.6 10.9 (42.7) 0 0.1 −0.1 Katz et al. [7 ] 2015 1 iStent 38 18 19.8 ± 1.3 15.6 ± 1.5 4.2 (21.2) 1.7 + 0.6 0.18 1.5 (89.5) 2 iStents 41 18 20.1 ± 1.6 13.8 ± 1.3 6.3 (31.3) 1.8 ± 0.5 0.12 1.6 (93.2) 3 iStents 40 18 20.4 ± 1.8 12.1 ± 1.2 8.3 (40.7) 1.5 ± 0.7 0.08 1.4 (94.7) Craven et al. [17 ] 2012 1 iStent + CS 116 24 18.6 ± 3.4 17.1 ± 2.9 1.5 (8.1) 1.6 ± 0.8 0.3 ± 0.6 1.3 (81.3) Fea [19 ] 2010 1 iStent + CS 12 16 17.9 ± 2.6 16.6 ± 3.1 1.3 (7.3) 2 ± 0.9 0 2 (100) Fernandez-Barrientos et al. [13 ] 2010 2 iStents + CS 17 12 24.2 ± 1.8† 17.6 ± 2.8 6.6 (27.3) 1.1 ± 0.5 0 1.1 (100) Lindstrom et al. [16 ] 2016 2 iStents 57 18 19.5 ± 1.5 14.4 ± 2.1 5.1 (26.2) 1 0.02 0.98 (98.0) Tan and Au [23 ] 2016 1 iStent + CS 41 36 21.2 ± 4.7 17.1 ± 2.4 4.1 (19.3) 2.1 ± 1.0 1.3 ± 1.2 0.8 (38.1) Donnenfeld et al. [10 ] 2015 2 iStents 39 36 20.6 ± 2.0 14.2 ± 2.1 6.4 (31.1) 1 0.05 0.95 (95.0) Fea et al. [20 ] 2015 1 iStent + CS 10 48 17.8 ± 2.7 15.9 ± 2.3 1.9 (10.7) 1.9 ± 0.9 0.5 ± 0.8 1.4 (74.7) Neuhann [22 ] 2015 1 iStent + CS 62 36 24.1 ± 6.9 14.9 ± 2.3 9.2 (38.2) 1.8 ± 0.9 0.3 ± 0.5 1.5 (83.3) Ahmed et al. [11 ] 2014 2 iStents 39 12 22.2 ± 2.0 17.1 ± 2.2 5.1 (23.0) 2 1 1 (50.0) Arriola-Villalobos et al. [12 ] 2013 2 iStents + CS 20 12 20.0 ± 3.7 16.8 ± 2.2 3.2 (16.0) 1.3 ± 0.7 0.3 ± 0.6 1 (76.9) Patel et al. [26 ] 2013 1 iStent ± CS 44 6 21.5 16.7 4.8 (22.3) 2.3 0.6 1.7 (73.9) Arriola-Villalobos et al. [25 ] 2012 1 iStent + CS 19 36 19.4 ± 1.9 16.3 ± 4.2 3.2 (16.3) 1.3 ± 0.5 0.8 ± 0.9 0.48 (36.4) Buchacra et al. [9 ] 2011 1 iStent 10 12 26.5 ± 7.9 17.0 ± 2.5 9.5 (35.8) 2.9 ± 0.7 1.1 ± 0.6 1.8 (62.1) Samuelson et al. [18 ] 2011 1 iStent + CS 111 12 18.4 ± 3.2 16.9 ± 3.0 1.5 (8.2) 1.5 ± 0.6 0.2 ± 0.6 1.3 (86.7) Vandewalle et al. [24 ] 2009 1 iStent ± CS 10 12 19.6 15.8 3.8 (19.4) 2.7 1.7 1 (37.0) Spiegel et al. [27 ] 2009 1 iStent ± CS 47 12 21.5 ± 3.7 16.9 4.6 (21.4) 1.6 ± 0.8 0.4 1.2 (75.0) iStent inject Fea et al. [28 ] 2014 2 iStent injects 94 12 21.1 ± 1.7 13.0 ± 2.3 8.1 (38.4) 1 0.1 0.9 (91.5) Arriola-Villalobos et al. [30 ] 2016 1 iStent inject + CS 11 60 20.4 ± 4.5 16.2 ± 2.3 4.2 (20.5) 1.2 ± 0.8 1.1 ± 0.8 0.1 (7.6) Voskanyan et al. [29 ] 2014 2 iStent injects 99 12 22.1 ± 3.3 15.7 ± 3.7 6.4 (29.0) 2.2 ± 0.4 0.3 1.9 (87.3) Gonnermann et al. [31 ] 2016 2 iStent injects + CS 25 12 21.3 ± 4.1 14.0 ± 2.3 7.3 (34.0) 2.0 ± 0.9 1.3 ± 1.2 0.7 (36.0) Klamann et al. [65 ] 2015 1 iStent inject†† 17 6 21.2 ± 2.6 14.2 ± 1.4 7 (33.0) 2.2 ± 0.9 0.9 ± 0.6 1.3 (59.8) 1 iStent inject†† 15 6 23.8 ± 3.3 15.3 ± 1.1 8.4 (35.5) 2.3 ± 1.2 1.0 ± 0.3 1.3 (55.4) 1 iStent inject†† 3 6 28.3 ± 3.2 N.A. N.A. N.A. N.A. N.A. Hydrus Pfeiffer et al. [32 ] 2015 Hydrus + CS 50 24 18.9 ± 3.3 16.9 ± 3.3 2.0 (10.6) 2.0 ± 1.0 0.5 ± 1.0 1.5 (75.0) Fea et al. [33 ] 2016 Hydrus 31 12 23.1 ± 5.1 16.5 ± 2.6 6.6 (28.5) 2.3 ± 0.8 0.9 ± 1.0 1.4 (60.7) Gandolfi et al. [34 ] 2016 Hydrus 21 24 26.0 ± 4.0 16.0 ± 2.0 10.0 (38.5) 2.7 0.9 ± 1.0 1.8 (66.9) Suprachoroidal devices CyPass Vold et al. [15 ] 2016 CyPass + CS 374 24 24.4 ± 2.8† 17.0 ± 3.4 7.4 (30.3) 1.4 ± 0.9 0.2 ± 0.6 1.2 (85.7) Hoeh et al. [53 ] 2016 CyPass + CS 142 12 20.2 ± 6.0 15.9 ± 3.1 4.3 (21.3) 2.0 ± 1.1 1.1 0.9 (45.0) Garcia-Feijoo et al. [54 ] 2015 CyPass 65 12 24.5 ± 2.8 16.4 ± 5.5 8.1 (33.1) 2.2 ± 1.1 1.4 ± 1.3 0.8 (36.4) Hoeh et al. [52 ] 2013 CyPass + CS 184 6 21.1 ± 5.9 15.6 ± 0.5 5.5 (26.1) 2.1 ± 1.1 0.8 1.35 (64.3) Subconjunctival devices XEN-45 Perez-Torregrosa et al. [55 ] 2016 XEN-45 + CS 30 12 21.2 ± 3.4 15.0 ± 2.5 6.2 (29.1) 3.1 ± 0.7 0.2 ± 0.7 2.9 (94.5) InnFocus Batlle et al. [63 ] 2016 InnFocus ± CS 23 36 23.8 ± 5.3 10.7 ± 3.5 13.1 (55.0) 2.4 ± 1.0 0.7 ± 1.1 1.7 (70.8)
CS: cataract surgery; ELT: excimer laser trabeculotomy; IOP: intraocular pressure;
